Mediation
Pharma’s Future at Stake: Trump’s Victory and Its Implications for Drug Pricing Reform
Donald Trump, Kamala Harris, 2024 Presidential Election, Drug Pricing Reform, Inflation Reduction Act, Medicare Price Negotiations, Pharmaceutical Industry, Biopharma.
CMS Prepares for Second Round of Medicare Drug Price Negotiation Program
Medicare Drug Price Negotiation Program, CMS, drug price negotiations, Inflation Reduction Act, Part D drugs, maximum fair prices (MFPs)
Novo Nordisk’s Ozempic Expected to Face Medicare Price Negotiations in 2025
Ozempic, Medicare, price negotiations, Novo Nordisk, diabetes medication, Inflation Reduction Act
Novo Nordisk Faces Setback in IRA Litigation, Vows to Appeal
Novo Nordisk, IRA lawsuit, Medicare price negotiations, legal setback, appeal
IRA Drug Price Reductions Unlikely to Harm Biotech Innovation, Studies Suggest
Inflation Reduction Act, IRA, drug price negotiations, biotech innovation, Medicare, pharmaceutical industry
AstraZeneca Appeals IRA Loss, Reiterates Constitutional Challenge to Drug Price Negotiations
AstraZeneca, IRA, Medicare, Drug Price Negotiation, Constitutional Challenge, Appeal
WHO Negotiations Extended for Global Pandemic Agreement
World Health Organization (WHO), pandemic accord, international agreement, global health, deadline, negotiations, public health emergency, disease outbreaks.
Medicare Partially Covers Weight Loss Drugs Amidst High Price Concerns and Future Negotiation Prospects
Medicare, Obesity drugs, Wegovy, Semaglutide, Price negotiation, Affordability, Accessibility, Premium increases, Utilization management
Biden Proposes Expansion of Medicare Drug Price Negotiation Program
Biden, Medicare, Drug Prices, Negotiation, Increased Scrutiny, More Drugs, Health Care Policy